Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYP-001 + corticosteroids
- Development stage
- Unknown
- Lead developer
- Cynata Therapeutics
- Modality
- Small Molecules, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
CYP-001 + corticosteroids is a combination therapy being developed by Cynata Therapeutics for the treatment of high-risk acute graft versus host disease (aGvHD). CYP-001 is the lead product candidate from Cynata's proprietary Cymerus platform, consisting of off-the-shelf, induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs). These MSCs are intended to exert immunomodulatory effects by reducing inflammation and restoring immune balance in patients where donor immune cells attack recipient tissues following allogeneic stem cell transplantation. Corticosteroids, such as prednisone or methylprednisolone, serve as the standard-of-care anti-inflammatory component of the regimen. The combination is currently being evaluated in a Phase 2 randomized, double-blind, placebo-controlled study to assess its efficacy and safety compared to corticosteroids alone.
- Other names
- CYP-001 plus corticosteroidsCYP001 plus corticosteroidsCYP 001 plus corticosteroidsCymerus iPSC-derived MSCs plus corticosteroidsCYP-001 in combination with corticosteroidsCYP001 in combination with corticosteroidsCYP 001 in combination with corticosteroids
Beyond the preview
Go deeper on CYP-001 + corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP-001 + corticosteroids.